G01N 33/57595
Involving intracellular compounds
Official title: {involving intracellular compounds}
G01N33/57595 (Involving intracellular compounds) appears on 586 US grants and 1,097 published applications in this corpus.
Search patents in G01N- Granted patents
- 586
- Published applications
- 1,097
- Assignees
- 609
- Inventors
- 2,299
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 7 | 0 |
| 1998 | 14 | 0 |
| 1999 | 16 | 0 |
| 2000 | 13 | 0 |
| 2001 | 10 | 4 |
| 2002 | 7 | 19 |
| 2003 | 5 | 34 |
| 2004 | 7 | 18 |
| 2005 | 4 | 25 |
| 2006 | 7 | 37 |
| 2007 | 12 | 32 |
| 2008 | 15 | 32 |
| 2009 | 11 | 34 |
| 2010 | 19 | 46 |
| 2011 | 17 | 30 |
| 2012 | 12 | 44 |
| 2013 | 20 | 38 |
| 2014 | 24 | 86 |
| 2015 | 25 | 100 |
| 2016 | 33 | 95 |
| 2017 | 43 | 73 |
| 2018 | 41 | 55 |
| 2019 | 52 | 51 |
| 2020 | 30 | 52 |
| 2021 | 29 | 42 |
| 2022 | 18 | 37 |
| 2023 | 23 | 39 |
| 2024 | 19 | 31 |
| 2025 | 28 | 24 |
| 2026 | 12 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of determining risk of and treating cancer recurrence22 Sep 2026US 12,742,782 B2The Regents of the University of Michigan
- Compositions and methods for monitoring, diagnosis, detection and treatment of cancer8 Sep 2026US 12,728,115 B2GLAX Health LLC
- Interferon pathway genes regulate and predict efficacy of immunotherapy23 Jun 2026US 12,662,705 B2The Trustees of the University of Pennsylvania
- Quantitative centrosomal amplification score to predict local recurrence of ductal carcinoma in situ9 Jun 2026US 12,650,430 B2Georgia State University Research Foundation, Inc.
- PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target26 May 2026US 12,637,498 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods for detection of aberrant cdk5 expression8 Oct 2026US 2026/0309712 A1Arizona Board of Regents on Behalf of the University of Arizona
- Anti-human homeobox protein nkx-2.1 antibodies for use in immunohistochemistry (ihc) protocols and for diagnosing cancer24 Sep 2026US 2026/0285955 A1Agilent Technologies, Inc.
- Microbiota-associated markers of high-grade squamous intraepithelial lesions (hsil)17 Sep 2026US 2026/0276641 A1
- Novel inhibitors of histone methyltransferase nuclear localisation20 Aug 2026US 2026/0242753 A1The Council of the Queensland Institute of Medical Research
- Method of predicting success of a cancer therapy13 Aug 2026US 2026/0235610 A1Immusmol SAS
Most cited
By later US patents
- Class characterization of circulating cancer cells isolated from body fluids and methods of use160US 6,960,449 B2Cell Works Diagnostics, Inc. · 2005
- Sequence specific DNA binding by p53109US 5,362,623 APharmaGenics, Inc. · 1994
- Detection of necrotic malignant tissue and associated therapy104US 4,861,581 ACancer Biologics, Inc. · 1989
- Detection of necrotic malignant tissue and associated therapy93US 5,019,368 ACancer Biologics, Inc. · 1991
- Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis88US 5,310,653 ABoard of Regents, The University of Texas System · 1994